A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.
VEGF
alternative splicing
angio/lymphangiogenesis
renal cell carcinoma
resistance to antiangiogenics
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
04
12
2022
accepted:
20
02
2023
medline:
7
7
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
The efficacy of anti-angiogenic treatment by targeting VEGF/VEGF receptors in metastatic clear cell renal cell carcinoma (ccRCC) varies from patient to patient. Discovering the reasons behind this variability could lead to the identification of relevant therapeutic targets. Thus, we investigated the novel splice variants of VEGF that are less efficiently inhibited by anti-VEGF/VEGFR targeting than the conventional isoforms. By in silico analysis, we identified a novel splice acceptor in the last intron of the VEGF gene resulting in an insertion of 23 bp in VEGF mRNA. Such an insertion can shift the open-reading frame in previously described splice variants of VEGF (VEGF
Identifiants
pubmed: 36810959
doi: 10.1002/1878-0261.13401
pmc: PMC10323879
doi:
Substances chimiques
Protein Isoforms
0
Angiogenesis Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT00943839']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1379-1401Informations de copyright
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Lancet Oncol. 2022 Jul;23(7):e318
pubmed: 35772460
Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612
pubmed: 29239846
Clin Cancer Res. 2012 Nov 15;18(22):6384-91
pubmed: 23104894
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Mol Cancer Ther. 2018 Jul;17(7):1355-1364
pubmed: 29967214
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Angiogenesis. 2017 Nov;20(4):463-478
pubmed: 28741165
Oncogene. 2012 Mar 29;31(13):1683-94
pubmed: 21909141
Cancer Res. 2013 Jul 15;73(14):4579-4590
pubmed: 23689123
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Saudi Pharm J. 2012 Oct;20(4):381-5
pubmed: 23960813
J Clin Oncol. 2018 Mar 10;36(8):765-772
pubmed: 29309249
Commun Biol. 2021 Feb 5;4(1):166
pubmed: 33547392
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
Mol Cancer. 2010 Dec 31;9:320
pubmed: 21194429
Cancer Res. 2017 Mar 1;77(5):1212-1226
pubmed: 28087600
Mol Cell Biol. 2009 May;29(10):2570-81
pubmed: 19273585
Lancet. 2007 Dec 22;370(9605):2103-11
pubmed: 18156031
Lancet Oncol. 2016 Jan;17(1):e4-5
pubmed: 26758760
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
J Clin Oncol. 2010 May 1;28(13):2144-50
pubmed: 20368553
Cell. 1996 Aug 9;86(3):353-64
pubmed: 8756718
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Clin Oncol. 2010 Jan 20;28(3):475-80
pubmed: 20008644
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cell. 2006 Mar 24;124(6):1283-98
pubmed: 16564017
Cell. 2014 Jun 19;157(7):1605-18
pubmed: 24949972
Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61
pubmed: 24220935
J Clin Oncol. 2013 Oct 20;31(30):3791-9
pubmed: 24019545
Genes Cancer. 2011 Dec;2(12):1097-105
pubmed: 22866201
Vasc Health Risk Manag. 2006;2(3):213-9
pubmed: 17326328
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Br J Cancer. 2017 Sep 26;117(7):947-953
pubmed: 28850564
Theranostics. 2018 Mar 28;8(9):2447-2458
pubmed: 29721091
Science. 1989 Dec 8;246(4935):1306-9
pubmed: 2479986
J Cell Biol. 2010 Jan 11;188(1):115-30
pubmed: 20065093
Cancer Res. 2008 Nov 1;68(21):8667-72
pubmed: 18974107
Eur Urol Focus. 2016 Feb;1(3):284-290
pubmed: 28723401
Theranostics. 2021 Sep 21;11(19):9571-9586
pubmed: 34646387
Trends Cell Biol. 2001 Nov;11(11):S32-6
pubmed: 11684440
Methods Mol Biol. 2015;1332:3-23
pubmed: 26285742
Nat Rev Cancer. 2008 Nov;8(11):880-7
pubmed: 18923433
Br J Cancer. 2018 May;118(9):1179-1188
pubmed: 29563634
J Biol Chem. 2002 Aug 16;277(33):29992-8
pubmed: 12021274
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Clin Genitourin Cancer. 2018 Aug;16(4):266-273
pubmed: 29503246
Science. 1989 Dec 8;246(4935):1309-12
pubmed: 2479987
EMBO J. 1989 Dec 1;8(12):3801-6
pubmed: 2684646
Cell. 2016 Sep 22;167(1):275-284.e6
pubmed: 27662093
Science. 2005 Feb 18;307(5712):1098-101
pubmed: 15718470
Cell. 2007 Aug 24;130(4):691-703
pubmed: 17719546
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Theranostics. 2020 Jan 1;10(3):1107-1121
pubmed: 31938054
J Clin Oncol. 2009 Jul 10;27(20):3312-8
pubmed: 19451442
Expert Rev Anticancer Ther. 2008 Jan;8(1):63-73
pubmed: 18095884
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
Exp Cell Res. 2006 Mar 10;312(5):549-60
pubmed: 16336962
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22910-22919
pubmed: 32859758